Physician profile
Muhammad Saad
NPI 1083090278
$8,471.67
in general payments reported to CMS, 2019-2025
32 companies · $1,899 in 2025
The $1,899 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $391 · 2021: $924 · 2022: $884 · 2023: $654 · 2024: $3,720 · 2025: $1,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,739 · Travel and Lodging: $1,405 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,738.95 |
| Travel and Lodging | $1,405.03 |
| Education | $129.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,167.68 | 2021-2025 | Cardiomems, Optis, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $464.23 | 2021-2023 | Azure Xt Dr Mri Surescan |
| Angiodynamics, INC. | $372.22 | 2024-2025 | Angiovac, Alphavac |
| Edwards Lifesciences Corporation | $353.51 | 2023-2025 | Pascal, Hemosphere |
| Janssen Pharmaceuticals, INC | $338.36 | 2021-2022 | |
| Boston Scientific Corporation | $327.36 | 2020-2024 | Sentinel |
| Amgen INC. | $325.08 | 2021-2025 | Repatha, Repatha |
| Astellas Pharma US INC | $319.50 | 2020-2022 | |
| Abiomed | $300.75 | 2024-2025 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $296.98 | 2020-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $259.55 | 2023-2025 | Farxiga, Wainua, Lokelma |
| Pfizer INC. | $259.16 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $181.78 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Shockwave Medical, INC | $181.63 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $165.14 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragonix Technologies, INC. | $160.04 | 2024 | |
| Novartis Pharmaceuticals Corporation | $140.40 | 2022-2023 | |
| Ancora Heart, INC. | $137.72 | 2024 | Accucinch |
| Merck Sharp & Dohme LLC | $127.65 | 2022-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $110.01 | 2024-2025 | Onpattro |
| Daiichi Sankyo INC. | $108.32 | 2023-2025 | Injectafer, Vanflyta |
| Biotronik INC. | $92.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.53 | 2022-2024 | Jardiance |
| Lantheus Medical Imaging, INC. | $43.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.32 | 2020-2025 | Eliquis |
| Esperion Therapeutics, INC. | $29.81 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $26.99 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $22.00 | 2020 | |
| Bridgebio Pharma, INC. | $19.71 | 2025 | Attruby |
| Chiesi USA, INC. | $19.40 | 2020 | |
| Biosense Webster, INC. | $19.24 | 2021 | |
| Philips North America LLC | $15.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.